Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02659865 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3039478 in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT02659865 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 29 participants.
The verdict
NCT02659865, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
The main purpose of this study is to investigate the safety of the study drug known as LY3039478 and evaluate two different formulations of LY3039478 in healthy participants. Part A has three periods. Either LY3039478 or placebo will be given once by mouth in each period. Part B has two periods. Participants will receive both formulations of LY3039478, by mouth, over the course of the study. Both parts of the study will also explore how much LY3039478 gets into the bloodstream and how long it takes the body to get rid of it. Information about any side effects will also be collected. Participants may only enroll in one part. The study will last at least 33 days, not including screening. Screening must be performed up to 30 days before enrollment. Part B was added by protocol amendment approved in April, 2016.
Interventions
- DRUG Placebo
- DRUG LY3039478 Capsule Formulation (Formulation 3)
- DRUG LY3039478 Drug-in Capsule (Reference, Formulation 1)
- DRUG LY3039478 Formulated Capsule (Test, Formulation 3)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2016-01 |
| Est. Completion | 2016-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02659865
The ClinicalTrials.gov registry entry for NCT02659865 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02659865 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02659865 about?
NCT02659865 is a clinical study titled "A Study of LY3039478 in Healthy Participants". The main purpose of this study is to investigate the safety of the study drug known as LY3039478 and evaluate two different formulations of LY3039478 in healthy participants. Part A has three periods. Either LY3039478 or placebo will be given once by mouth in each period. Part B has two periods. Par...
What is the current status of trial NCT02659865?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2016-01. Estimated completion is 2016-06.
What interventions are being tested in trial NCT02659865?
The interventions under investigation include: Placebo (DRUG), LY3039478 Capsule Formulation (Formulation 3) (DRUG), LY3039478 Drug-in Capsule (Reference, Formulation 1) (DRUG), LY3039478 Formulated Capsule (Test, Formulation 3) (DRUG).
Who is sponsoring clinical trial NCT02659865?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.